FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma

Perspective Therapeutics, Inc.

Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.
Designation enables more frequent FDA interactions and eligibility for accelerated/priority/rolling review.
Phase 1/2a Cohort 2 DLT observation period completed; safety data to be shared with SMC and scientific forum.
Company plans to open VMT01/anti-PD-1 combination cohort pending IRB approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.